ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full...(tions necessary to supportthe extension ...)

Date:3/31/2008

tions necessary to support the extension of expiration dating for urokinase inventory to between July and September of 2009. The Company submitted for and the FDA approved the release of three lots of urokinase during the first quarter of 2008 under the new Kinlytic trade name. The Company believes this labeled inventory will be sufficient to meet market demand through September 2009. ImaRx intends to continue its stability program to evaluate the potential for further expiration extensions beyond September 2009 for unlabeled vials of urokinase inventory.

Bradford A. Zakes stated, "The extension of the expiration dating and FDA approval of our recent requests for lot release represent a significant accomplishment for ImaRx, by allowing us to generate additional value from the continued sale of our urokinase inventory well into 2009. We remain confident that the stability profile of our urokinase inventory will enable us to achieve future expiration date extensions as we market the balance of our existing unlabeled vials of urokinase."

In January 2008 ImaRx signed a Letter of Intent with Microbix Biosystems Inc. (TSE: MBX) to manufacture and continue selling urokinase beyond the existing inventory. Closing of the transaction is dependent upon the satisfactory completion of due diligence and Microbix securing adequate financing to transfer the manufacturing process. A new supply of urokinase would allow ImaRx to continue to serve its current customers. It also would provide the opportunity to expand sales to additional vascular physicians and acute care institutions and to explore clinical development of urokinase for additional vascular indications.

In connection with the urokinase acquisition in April 2006, the Company issued a $15.0 million non-recourse promissory note to Abbott that matures on March 31, 2008. The outstanding balance of the note plus accrued interest, net of funds in escrow, is $10.8 million. The Company has reached a tentative
'/>"/>

SOURCE ImaRx Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. ImaRx to Report Corporate Updates and 4Q07 Financial Results
3. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination